Fig. 2. Evaluation and management of bone health in (A) women and (B) men with differentiated thyroid cancer under TSH suppressive therapy. 1The high-risk group for osteoporosis and fragility fractures includes a previous history of fragility fractures, more than 1 year of amenorrhea in women, having other medical diseases or taking medications that cause osteoporosis. 2Ca/D+Osteoporosis Tx, Treatment for osteoporosis is needed in combination with calcium and vitamin D replacement. 3Ca/D±Osteoporosis Tx, Treatment for osteoporosis can be considered in combination with calcium and vitamin D replacement. Anti-osteoporosis treatment includes anti-resorptive agents (e.g., bisphosphonate) and anabolic agents. Certain types of bisphosphonates (i.e., ibandronate) are not available in men. BMD: bone mineral density, Ca/D: calcium and vitamin D, DTC: differentiated thyroid cancer, DXA: dual-energy X-ray absorptiometry, TSH: thyroid stimulating hormone, Tx: therapy
© 2022 Int J Thyroidol